TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.48, sa.1, ss.54-56, 2014 (SCI-Expanded)
Imatinib is the first molecularly targeted drug developed for the treatment of chronic myeloid leukemia (CML). Adverse cutaneous reactions induced by imatinib are frequent and generally moderate. On the other hand, imatinib-induced erythroderma is an uncommon reaction, and only a few cases have been reported in the literature. In this paper, we report a case of erythrodermia induced by imatinib in a patient with CML.